- Home
- TOPS vs LSTA Comparison
TOPS vs LSTA Comparison
Compare TOPS & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- LSTA
- Stock Information
- Founded
- TOPS 2000
- LSTA 1980
- Country
- TOPS Greece
- LSTA United States
- Employees
- TOPS N/A
- LSTA N/A
- Industry
- TOPS Marine Transportation
- LSTA Misc Health and Biotechnology Services
- Sector
- TOPS Consumer Discretionary
- LSTA Health Care
- Exchange
- TOPS Nasdaq
- LSTA Nasdaq
- Market Cap
- TOPS 28.3M
- LSTA 31.2M
- IPO Year
- TOPS 2004
- LSTA N/A
- Fundamental
- Price
- TOPS $5.83
- LSTA $2.55
- Analyst Decision
- TOPS
- LSTA Strong Buy
- Analyst Count
- TOPS 0
- LSTA 1
- Target Price
- TOPS N/A
- LSTA $15.00
- AVG Volume (30 Days)
- TOPS 6.2K
- LSTA 24.3K
- Earning Date
- TOPS 03-28-2025
- LSTA 02-27-2025
- Dividend Yield
- TOPS N/A
- LSTA N/A
- EPS Growth
- TOPS N/A
- LSTA N/A
- EPS
- TOPS N/A
- LSTA N/A
- Revenue
- TOPS $83,870,000.00
- LSTA N/A
- Revenue This Year
- TOPS $7.10
- LSTA N/A
- Revenue Next Year
- TOPS $6.54
- LSTA N/A
- P/E Ratio
- TOPS N/A
- LSTA N/A
- Revenue Growth
- TOPS 1.10
- LSTA N/A
- 52 Week Low
- TOPS $5.30
- LSTA $2.19
- 52 Week High
- TOPS $14.70
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- TOPS 36.66
- LSTA 42.39
- Support Level
- TOPS $5.78
- LSTA $2.41
- Resistance Level
- TOPS $6.11
- LSTA $2.66
- Average True Range (ATR)
- TOPS 0.27
- LSTA 0.19
- MACD
- TOPS -0.01
- LSTA 0.01
- Stochastic Oscillator
- TOPS 9.99
- LSTA 42.06
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The company focuses on the transportation of petroleum products (clean and dirty) and bulk liquid chemicals. The Company is an international provider of worldwide oil, petroleum products and chemical transportation services. It generates revenue from the Time Charter agreements.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.